Nuformix PLC Patent Update

RNS Number : 5819S

Nuformix PLC

17 June 2024

 

17 June 2024

 

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Patent Update

​

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following patent update:

NXP002

NXP002 is the Company's lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF") for which the Company holds multiple patents:

·    NXP002 Substance of Matter: Following grants in the US and Japan, the European Patent Office formally issued a grant of patent number 3837238 on 12 June 2024 covering the Company's proprietary NXP002 drug forms being progressed by the Company as a potential novel IPF treatment.

·    NXP002 Method of Use: The US PTO issued a grant of patent application 17/365,490 on 14 June 2024, covering use of the Company's proprietary drug forms in the treatment of various diseases including fibrotic lung diseases.

·    NXP002 Compositions for Treatment: Now in national filing stages and proceeding through examination.

NXP004

The Company's NXP004 programme is focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza® brand name. On 14 June 2024 the US Patent and Trademark Office ("PTO") has granted the Company patent number 12012386 covering the lead cocrystals under development, representing the first granted patent in this second NXP004 cocrystal series.  

Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we've received these multiple grants of key patents underpinning both our NXP002 and NXP004 programmes. The European patent grant represents the last major territory to confirm protection of the novel drug forms enabling NXP002's development as a potential novel IPF treatment. Granting of the method of use patent in the US further strengthens our IP position for this programme. The US PTO's decision to grant the patent protecting the NXP004 programme's lead cocrystals is also a first, with other territories soon to follow. The granting of these patents is very helpful and timely in progressing on-going discussions with potential development partners."

 

Enquiries:

 

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
Bob Pountney (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDQZLFFZQLXBBL